| Efficacy of high-dose methotrexate, ifosfamide, etoposide and dexamethasone salvage therapy for recurrent or refractory childhood malignant lymphoma. | |
| | |
MedLine Citation:
|
PMID: 20624787 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Children with recurrent or refractory malignant lymphoma generally have a poor prognosis. There is a need for new active drug combinations for this high-risk group of patients. PATIENTS AND METHODS: This study evaluated the activity and toxicity of the methotrexate, ifosfamide, etoposide and dexamethasone (MIED) regimen for childhood refractory/recurrent non-Hodgkin's lymphoma (NHL) or Hodgkin's lymphoma (HL). From 1991 through 2006, 62 children with refractory/recurrent NHL (n = 24) or HL (n = 38) received one to six cycles of MIED. Based on MIED response, intensification with hematopoietic stem cell transplantation (HSCT) was considered. RESULTS: There were 10 complete (CR) and 5 partial responses (PR) among the 24 children with NHL [combined response rate, 63%; 95% confidence interval (CI) 38% to 73%]. There were 13 CR and 18 PR among the 37 assessable children with HL (combined response rate, 84%; 95% CI, 68% to 94%). Although 59% courses were associated with grade IV neutropenia, treatment was well tolerated and without toxic deaths. CONCLUSIONS: MIED is an effective regimen for refractory/recurrent childhood malignant lymphoma, permitting a bridge to intensification therapy with HSCT. |
| | |
Authors:
|
J T Sandlund; C-H Pui; H Mahmoud; Y Zhou; E Lowe; S Kaste; L E Kun; M J Krasin; M Onciu; F G Behm; R C Ribeiro; B I Razzouk; S C Howard; M L Metzger; G A Hale; R Rencher; K Graham; M M Hudson |
Related Documents
:
|
22095247 - Cervical stromal involvement can predict survival in advanced endometrial carcinoma: a ... 22229927 - Re-consideration of lymphadenectomy for stage ib1 cervical cancer. 4005797 - Bowel perforation during initial treatment for childhood non-hodgkin's lymphoma. 7751877 - Clinical and prognostic significance of bone marrow involvement in patients with diffus... 19443337 - Management and prognosis in synchronous solitary resected brain metastasis from non-sma... 15163277 - A review of the proteasome inhibitor bortezomib in multiple myeloma. |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural Date: 2010-07-12 |
Journal Detail:
|
Title: Annals of oncology : official journal of the European Society for Medical Oncology / ESMO Volume: 22 ISSN: 1569-8041 ISO Abbreviation: Ann. Oncol. Publication Date: 2011 Feb |
Date Detail:
|
Created Date: 2011-01-31 Completed Date: 2011-05-02 Revised Date: 2012-02-01 |
Medline Journal Info:
|
Nlm Unique ID: 9007735 Medline TA: Ann Oncol Country: England |
Other Details:
|
Languages: eng Pagination: 468-71 Citation Subset: IM |
Affiliation:
|
Department of Oncology, St Jude Children's Research Hospital, University of Tennessee, Memphis, TN, USA. John.Sandlund@stjude.org |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antineoplastic Combined Chemotherapy Protocols
/
adverse effects,
therapeutic use* Child Dexamethasone / administration & dosage Etoposide / administration & dosage Hodgkin Disease / drug therapy*, pathology Humans Ifosfamide / administration & dosage Lymphoma, Non-Hodgkin / drug therapy*, pathology Methotrexate / administration & dosage Recurrence Salvage Therapy |
| Grant Support | |
ID/Acronym/Agency:
|
CA 21765/CA/NCI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
33419-42-0/Etoposide; 3778-73-2/Ifosfamide; 50-02-2/Dexamethasone; 59-05-2/Methotrexate |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Positron emission tomography/computed tomography in the management of recurrent/metastatic breast ca...
Next Document: Effect of oral exposure to fenitrothion and 3-methyl-4-nitrophenol on splenic cell populations and h...